Loading ...
Sorry, an error occurred while loading the content.
 

Article-FYI

Expand Messages
  • byteme
    This is just a new item on HCV. If it does not get on the list, E-mail me and I ll send a copy. Marty E-mail byteme@insideseminole.com Chiron Granted
    Message 1 of 1 , Mar 6, 2000
      This is just a new item on HCV. If it does not get on the list, E-mail
      me and I'll send a copy. Marty E-mail byteme@...

      Chiron Granted Hepatitis C Patent

      Discovery Research Broadens Intellectual Property Position

      EMERYVILLE, Calif., March 6 /PRNewswire/ -- Chiron Corporation (Nasdaq:

      CHIR) today announced that it has been granted United States Patent No.
      6,027,729. This patent is directed to hepatitis C polypeptides encoded
      throughout the genomes of hepatitis C viruses (HCV). The polypeptides
      can
      be from the core, envelope, or non-structural regions of any strain of
      hepatitis C virus. Immunologically reactive HCV polypeptides, including

      large recombinant proteins and shorter synthetic peptides, are used in
      immunoassays for both screening blood donations and in clinical
      diagnosis
      of HCV infection. Such polypeptides are also being used in the
      development of vaccines to stimulate protective immune responses, and as

      targets in the development of new anti-HCV therapeutics. These
      polypeptides are also used to screen and produce anti-HCV antibody
      preparations.

      "This patent is based on a fundamental breakthrough in infectious
      disease
      research which Chiron scientists achieved when they cloned and correctly

      identified the hepatitis C virus," commented Robert Blackburn, vice
      president and chief patent counsel at Chiron. "Never before had an
      unknown infectious agent been identified through molecular cloning
      techniques alone without prior characterization. This invention has
      resulted in saving millions of people from a potentially debilitating
      and
      sometimes fatal disease. Likewise it has enabled healthcare systems
      worldwide to save millions of dollars in detection and treatment costs."

      Hepatitis C, previously called non-A, non-B hepatitis, has been known
      since the mid 1970s and became recognized as a major health threat to
      patients receiving blood transfusions. In response to this crisis,
      major
      laboratories around the world searched without success for the
      disease-causing agent. In 1987, Chiron scientists Michael Houghton,
      Ph.D.; Qui-Lim Choo, Ph.D.; and George Kuo, Ph.D., cloned and first
      identified HCV as the cause of transfusion-related non-A, non-B
      hepatitis.
      This discovery marked the first time a virus was cloned before it had
      been
      grown in tissue culture or otherwise isolated. Based on its research,
      Chiron has been granted in excess of 100 HCV-related patents in over 20
      countries.

      About Chiron Corporation

      Chiron Corporation, headquartered in Emeryville, California, is a
      leading
      biotechnology company that participates in three global healthcare
      markets: biopharmaceuticals, vaccines, and blood testing. The company
      is
      applying a broad and integrated scientific approach to the development
      of
      innovative products for preventing and treating cancer, infectious
      diseases, and cardiovascular disease. For further information, visit
      the
      company's website at www.chiron.com.

      This document contains forward-looking statements that are subject to
      risk
      and uncertainty. There are a number of factors that could cause the
      company's actual performance to differ materially from expectations.
      These and other factors investors should consider are more thoroughly
      described in the company's Securities and Exchange Commission filings,
      including the Form 10-Q and Form 10-K.

      SOURCE Chiron Corporation
    Your message has been successfully submitted and would be delivered to recipients shortly.